MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Description

This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.

Conditions

Cutaneous Melanoma, Melanocytic Nevus, Skin Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.

Imaging Modalities for Melanoma Screening and Diagnosis

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Condition
Cutaneous Melanoma
Intervention / Treatment

-

Contacts and Locations

Portland

OHSU Knight Cancer Institute, Portland, Oregon, United States, 97239

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Persons who participate in the free skin cancer screening at the PDX Skincare Festival at Oregon Health \& Science University (OHSU) in 2021/2022 (date pending) and are informed by a provider that they have a pigmented lesion for which a biopsy is recommended are potentially eligible to participate in this study.
  • * Persons who participate in the free skin cancer screening at the War on Skin Cancer event at OHSU in 2021/2022 (date pending) or other dates and locations and are informed by a provider that they have a clinically benign or atypical nevi are eligible to participate in the imaging portion of this study. No biopsy will be offered to these participants.
  • * Persons age 18-80 are eligible for the study
  • * Persons of any race are eligible but we anticipate that most participants will be Non-Hispanic whites due to the prevalence of melanoma and other skin cancers in this group.
  • * Only persons who can provide signed statement of informed consent will be enrolled.
  • * Persons who are identified in OHSU Dermatology clinics or through OHSU e-visit and e-consult platforms as having a skin lesion in need of a biopsy for skin cancer
  • * Persons identified via the Melanoma Community Registry (MCR) (IRB approved: 00010561)
  • * Allergy to the anesthetic (lidocaine).

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

OHSU Knight Cancer Institute,

Joanna Ludzik, MD, PRINCIPAL_INVESTIGATOR, OHSU Knight Cancer Institute

Study Record Dates

2026-12-31